BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 12558747)

  • 1. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
    Nind NR; Attanoos RL; Gibbs AR
    Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
    Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
    Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
    Attanoos RL; Thomas DH; Gibbs AR
    Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Morphological diagnostics of malignant pleural mesothelioma].
    Junker K; Müller KM
    Pathologe; 2014 Nov; 35(6):586-90. PubMed ID: 25304423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation.
    Hinterberger M; Reineke T; Storz M; Weder W; Vogt P; Moch H
    Mod Pathol; 2007 Feb; 20(2):248-55. PubMed ID: 17361207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Pseudomesotheliomatous' carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff.
    Attanoos RL; Gibbs AR
    Histopathology; 2003 Nov; 43(5):444-52. PubMed ID: 14636270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathology of primary tumours of the pleura].
    Junker K; Krismann M
    Zentralbl Chir; 2008 Jun; 133(3):222-6. PubMed ID: 18563685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
    Johansson L; Lindén CJ
    Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
    Galateau-Salle F; Churg A; Roggli V; Travis WD;
    J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural mesothelioma classification-update and challenges.
    Dacic S
    Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pathology associated with therapeutic procedures in malignant mesothelioma.
    Attanoos RL; Gibbs AR
    Histopathology; 2004 Oct; 45(4):393-7. PubMed ID: 15469478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of pulmonary epithelioid hemangioendothelioma that required differentiation from malignant mesothelioma].
    Yanagi S; Sakamoto A; Tsubouchi H; Imai K; Imazu Y; Miyoshi K; Arimura Y; Kyoraku Y; Matsumoto N; Ashitani J; Nakazato M
    Nihon Kokyuki Gakkai Zasshi; 2010 May; 48(5):385-90. PubMed ID: 20560442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathohistological diagnosis and differential diagnosis.
    Tischoff I; Neid M; Neumann V; Tannapfel A
    Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of plakophilin 3 in diffuse malignant pleural mesothelioma.
    Mašić S; Brčić L; Krušlin B; Šepac A; Pigac B; Stančić-Rokotov D; Jakopović M; Seiwerth S
    Histol Histopathol; 2018 Sep; 33(9):995-1004. PubMed ID: 29722422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.